Gabriel N. Hortobagyi

Sep 12, 2024 | jamanetwork.com | Paolo Tarantino |Gabriel N. Hortobagyi |Sara M. Tolaney |Elizabeth A. Mittendorf

Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review Abstract Importance  Over the past 2 decades, systemic therapy for early-stage breast cancer has gradually moved from the adjuvant to the neoadjuvant setting. Administration of systemic therapy before surgery leads to potential improvements in surgical outcomes and allows for the assessment of the pathologic response to treatment.